| dc.contributor.author | Macfarlane, Gary | |
| dc.contributor.author | Biallas, R | |
| dc.contributor.author | Dean , LE | |
| dc.contributor.author | Jones, GT | |
| dc.contributor.author | Goodson, Nicola J | |
| dc.contributor.author | Rotariu, Ovidiu | |
| dc.date.accessioned | 2023-08-09T10:05:32Z | |
| dc.date.available | 2023-08-09T10:05:32Z | |
| dc.date.issued | 2023-02 | |
| dc.identifier | 216292418 | |
| dc.identifier | 6bd220c3-be44-411f-9161-3c0a35f78f0c | |
| dc.identifier | 35777821 | |
| dc.identifier | 85147317893 | |
| dc.identifier.citation | Macfarlane , G , Biallas , R , Dean , LE , Jones , GT , Goodson , N J & Rotariu , O 2023 , ' Inflammatory bowel disease risk in patients with axial spondyloarthritis treated with biologic agents : Determined Using the BSRBR-AS and a MetaAnalysis ' , Journal of Rheumatology , vol. 50 , no. 2 , pp. 175-184 . https://doi.org/10.3899/jrheum.211034 | en |
| dc.identifier.issn | 0315-162X | |
| dc.identifier.other | ORCID: /0000-0003-2322-3314/work/121059913 | |
| dc.identifier.uri | http://aura-test.abdn.ac.uk/handle/2164/19714 | |
| dc.description | Funding: The BSRBR-AS is supported by the British Society for Rheumatology and they have received funds for the registry from Pfizer, AbbVie and UCB. These companies have no input in determining the topics for analysis or work involved in undertaking it but do receive an advance copy of the manuscript on which they may make comments. ACKNOWLEDGEMENTS: The original idea for the study was suggested by John Mansfield and discussed with Lesley Kay (both Newcastle upon Tyne Hospitals NHS Foundation Trust). All authors discussed and contributed to designing this study and the analysis plan, which was undertaken by RLB and (updated and) overseen by OR, LED and GJM. Results were reviewed by all authors. GJM, RLB, OR and LED all contributed to drafting the manuscript which was critically reviewed by all authors. RLB undertook this work while a visiting student based at the University of Aberdeen from Ludwig-Maximilians Universität (Munich). | en |
| dc.format.extent | 1186563 | |
| dc.language.iso | eng | |
| dc.relation.ispartof | Journal of Rheumatology | en |
| dc.subject | axial spondyloarthritis | en |
| dc.subject | inflammatory bowel disease | en |
| dc.subject | registry | en |
| dc.subject | meta-analysis | en |
| dc.subject | TNFα | en |
| dc.subject | etanercept | en |
| dc.subject | biologics | en |
| dc.subject | R Medicine | en |
| dc.subject.lcc | R | en |
| dc.title | Inflammatory bowel disease risk in patients with axial spondyloarthritis treated with biologic agents : Determined Using the BSRBR-AS and a MetaAnalysis | en |
| dc.type | Journal article | en |
| dc.contributor.institution | University of Aberdeen.Vice Principals | en |
| dc.contributor.institution | University of Aberdeen.Epidemiology Group | en |
| dc.contributor.institution | University of Aberdeen.Aberdeen Centre for Arthritis and Musculoskeletal Health (ACAMH) | en |
| dc.contributor.institution | University of Aberdeen.Other Applied Health Sciences | en |
| dc.description.status | Peer reviewed | en |
| dc.identifier.doi | https://doi.org/10.3899/jrheum.211034 | |
| dc.date.embargoedUntil | 2022-12-10 | |
| dc.identifier.vol | 50 | en |
| dc.identifier.iss | 2 | en |
